Evidence map›Paper›PMID 38964748›Full record

ArticleBrain : a journal of neurology2024

Neuronal A2A receptor exacerbates synapse loss and memory deficits in APP/PS1 mice.

Victoria Gomez-Murcia, Agathe Launay, Kévin Carvalho, Anaëlle Burgard, Céline Meriaux, Raphaëlle Caillierez, Sabiha Eddarkaoui, Devrim Kilinc, Dolores Siedlecki-Wullich, Mélanie Besegher and 18 more

Abstract read
In one paragraph

Article in Brain : a journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Neurotransmitter Systems in Alzheimer's Disease.Current issues in molecular biology · 2026
    Review
  5. Article
  6. Upregulation of adenosine AMolecular psychiatry · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Victoria Gomez-MurciaUMR-S1172 Lille Neuroscience & Cognition (LilNCog), University of Lille, Inserm, CHU Lille, F-59000 Lille, France.
Agathe LaunayUMR-S1172 Lille Neuroscience & Cognition (LilNCog), University of Lille, Inserm, CHU Lille, F-59000 Lille, France.
Kévin CarvalhoUMR-S1172 Lille Neuroscience & Cognition (LilNCog), University of Lille, Inserm, CHU Lille, F-59000 Lille, France.
Anaëlle BurgardLaboratoire de Neuroscience Cognitives et Adaptatives (LNCA), University of Strasbourg, F-67000 Strasbourg, France.
Céline MeriauxUMR-S1172 Lille Neuroscience & Cognition (LilNCog), University of Lille, Inserm, CHU Lille, F-59000 Lille, France.
Raphaëlle CaillierezUMR-S1172 Lille Neuroscience & Cognition (LilNCog), University of Lille, Inserm, CHU Lille, F-59000 Lille, France.
Sabiha EddarkaouiUMR-S1172 Lille Neuroscience & Cognition (LilNCog), University of Lille, Inserm, CHU Lille, F-59000 Lille, France.
Devrim KilincInserm U1167, LabEx DISTALZ, Université de Lille, Institut Pasteur de Lille, CHU Lille, F-59000 Lille, France.ORCID 0000-0003-3321-5203
Dolores Siedlecki-WullichInserm U1167, LabEx DISTALZ, Université de Lille, Institut Pasteur de Lille, CHU Lille, F-59000 Lille, France.
Mélanie BesegherPlateformes Lilloises en Biologie et Santé (PLBS)-UAR 2014-US 41, CNRS, Inserm, Université de Lille, Institut Pasteur de Lille, CHU Lille, F-59000 Lille, France.
Séverine BégardUMR-S1172 Lille Neuroscience & Cognition (LilNCog), University of Lille, Inserm, CHU Lille, F-59000 Lille, France.
Bryan ThirouxUMR-S1172 Lille Neuroscience & Cognition (LilNCog), University of Lille, Inserm, CHU Lille, F-59000 Lille, France.
Matthieu JungInstitut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), University of Strasbourg, CNRS UMR7104, Inserm U1258-GenomEast Platform, F-67400 Illkirch, France.
Ouada NebieUMR-S1172 Lille Neuroscience & Cognition (LilNCog), University of Lille, Inserm, CHU Lille, F-59000 Lille, France.
Maxence WisztorskiInserm U1192, Protéomique Réponse Inflammatoire Spectrométrie de Masse (PRISM), Université de Lille, Lille F-59000, France.
Nicole DéglonLaboratory of Cellular and Molecular Neurotherapies (LCMN), Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Neuroscience Research Center (CRN), 1011 Lausanne, Switzerland.ORCID 0000-0003-4475-9476
Claire MontmassonInstitut du Fer à Moulin, Inserm UMR-S 1270, Sorbonne Université, F-75005 Paris, France.
Alexis-Pierre BemelmansLaboratoire des Maladies Neurodégénératives: mécanismes, thérapies, imagerie, Université Paris-Saclay, CEA, CNRS, F-92265 Fontenay-aux-Roses, France.
Malika HamdaneUMR-S1172 Lille Neuroscience & Cognition (LilNCog), University of Lille, Inserm, CHU Lille, F-59000 Lille, France.
Thibaud LebouvierUMR-S1172 Lille Neuroscience & Cognition (LilNCog), University of Lille, Inserm, CHU Lille, F-59000 Lille, France.
Didier VieauUMR-S1172 Lille Neuroscience & Cognition (LilNCog), University of Lille, Inserm, CHU Lille, F-59000 Lille, France.
Isabelle FournierInserm U1192, Protéomique Réponse Inflammatoire Spectrométrie de Masse (PRISM), Université de Lille, Lille F-59000, France.
Luc BueeUMR-S1172 Lille Neuroscience & Cognition (LilNCog), University of Lille, Inserm, CHU Lille, F-59000 Lille, France.ORCID 0000-0002-6261-4230
Sabine LéviInstitut du Fer à Moulin, Inserm UMR-S 1270, Sorbonne Université, F-75005 Paris, France.
Luisa V LopesInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina de Lisboa, Universidade de Lisboa, 1649-028 Lisboa, Portugal.ORCID 0000-0001-8367-3005
Anne-Laurence BoutillierLaboratoire de Neuroscience Cognitives et Adaptatives (LNCA), University of Strasbourg, F-67000 Strasbourg, France.
Emilie FaivreUMR-S1172 Lille Neuroscience & Cognition (LilNCog), University of Lille, Inserm, CHU Lille, F-59000 Lille, France.ORCID 0000-0002-8608-9848
David BlumUMR-S1172 Lille Neuroscience & Cognition (LilNCog), University of Lille, Inserm, CHU Lille, F-59000 Lille, France.ORCID 0000-0001-5691-431X

Funding

Agence National de la RechercheAssociation France AlzheimerCNRSDevelopment of Innovative Strategies for a Transdisciplinary approach to ALZheimer's diseaseFédération pour la Recherche sur le CerveauFondation AlzheimerFondation pour la Recherche MédicaleInsermUniversité de Lille
6 · The paper itself

Abstract

Early pathological upregulation of adenosine A2A receptors (A2ARs), one of the caffeine targets, by neurons is thought to be involved in the development of synaptic and memory deficits in Alzheimer's disease (AD) but mechanisms remain ill-defined. To tackle this question, we promoted a neuronal upregulation of A2AR in the hippocampus of APP/PS1 mice developing AD-like amyloidogenesis. Our findings revealed that the early upregulation of A2AR in the presence of an ongoing amyloid pathology exacerbates memory impairments of APP/PS1 mice. These behavioural changes were not linked to major change in the development of amyloid pathology but rather associated with increased phosphorylated tau at neuritic plaques. Moreover, proteomic and transcriptomic analyses coupled with quantitative immunofluorescence studies indicated that neuronal upregulation of the receptor promoted both neuronal and non-neuronal autonomous alterations, i.e. enhanced neuroinflammatory response but also loss of excitatory synapses and impaired neuronal mitochondrial function, presumably accounting for the detrimental effect on memory. Overall, our results provide compelling evidence that neuronal A2AR dysfunction, as seen in the brain of patients, contributes to amyloid-related pathogenesis and underscores the potential of A2AR as a relevant therapeutic target for mitigating cognitive impairments in this neurodegenerative disorder.

Indexed as

Alzheimer DiseaseAmyloid beta-Protein PrecursorMemory DisordersMice, TransgenicNeuronsReceptor, Adenosine A2ASynapsesAnimalsDisease Models, AnimalHippocampusMaleMiceMice, Inbred C57BLPlaque, AmyloidPresenilin-1Amyloid beta-Protein PrecursorPresenilin-1Receptor, Adenosine A2AA2A receptoradenosineAlzheimer’s diseaseSynapse loss

Identifiers

PMID38964748
PMCPMC11292904

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.